Coronary Artery Calcium Scoring: Should You Get One?
Dr. RP, MD — Board-Certified, Emergency Medicine & Critical Care Medicine — Founder, Analog Precision Medicine
Coronary artery calcium (CAC) scoring is a non-invasive cardiac imaging test that directly measures calcified atherosclerotic plaque in the coronary arteries using low-dose computed tomography. It is the most validated imaging test for predicting 10-year cardiovascular event risk currently available in clinical practice, and it provides information about the actual state of your coronary arteries — not an estimate of risk derived from population-level equations applied to your cholesterol level and age.
Despite strong evidence and formal guideline endorsement, CAC scoring remains underutilized in primary prevention cardiovascular practice. This article reviews the biology of coronary calcification, the evidence base for CAC scoring, how to interpret a CAC result, the populations most likely to benefit, and the genuine limitations of the test that patients and clinicians should understand.
What Is Coronary Artery Calcium?
Atherosclerosis is a chronic inflammatory process that begins with endothelial dysfunction and progresses through lipid accumulation, macrophage infiltration, foam cell formation, and fibrous cap development. Calcification is a late-stage feature of this process — it occurs in established atherosclerotic plaques and represents a form of pathologic mineralization driven by vascular smooth muscle cells that undergo osteogenic differentiation in the inflammatory milieu of advanced plaque.[1]
Calcium deposits are radiodense and are therefore detectable by computed tomography without intravenous contrast. CAC scoring uses a standardized non-contrast CT acquisition protocol (typically ECG-gated to minimize cardiac motion artifact) with the Agatston scoring algorithm, which calculates a score based on the area and peak Hounsfield unit density of calcified lesions across all four coronary arteries.[2]
The resulting Agatston score is unitless. A score of zero indicates no detectable calcified plaque. Higher scores correspond to greater calcified plaque burden. Scores are also reported as percentile ranks stratified by age, sex, and ethnicity using reference data from the Multi-Ethnic Study of Atherosclerosis (MESA).
Evidence Base
MESA (Multi-Ethnic Study of Atherosclerosis)
The largest and most influential CAC outcomes cohort. MESA enrolled 6,814 adults aged 45–84 without known cardiovascular disease and followed them for up to 10 years. A CAC score of zero at baseline was associated with a 10-year hard cardiovascular event rate of less than 2% — a rate so low it represented a "negative" result with sufficient reassurance to defer statin therapy in many intermediate-risk patients. Conversely, CAC ≥300 or CAC ≥75th percentile for age/sex/ethnicity predicted 10-year event rates approaching 20%.[3]
Detrano et al. NEJM 2008
Demonstrating that CAC outperformed standard risk scores, Framingham Risk Score, hsCRP, and carotid intima-media thickness (CIMT) as a predictor of coronary events in a prospective cohort of 6,722 asymptomatic adults.[4]
Pooled Cohort Equation Reclassification
Multiple studies have demonstrated that CAC significantly reclassifies patients whose 10-year cardiovascular risk is estimated at 5–20% by standard equations — precisely the "intermediate-risk" patients where the clinical decision to treat is most uncertain and where a definitive data point is most valuable.[5]
Statin Initiation Decision Support
The MESA derivation data enabled the development of the CAC-guided statin initiation framework endorsed by the 2018 ACC/AHA Cholesterol Guidelines. In intermediate-risk patients, a CAC score of zero provides sufficient reassurance to defer statin therapy in many patients; CAC ≥100 or ≥75th percentile supports statin initiation. This represents the first time an imaging biomarker has been formally incorporated into a major lipid guideline decision tree.[6]
Interpreting the CAC Score
CAC = 0 (Zero)
A CAC score of zero is a powerful negative finding. In the MESA cohort, zero-CAC individuals had a 10-year major adverse cardiovascular event rate of approximately 1–2%, comparable to the lowest-risk population strata. Multiple studies have demonstrated that a zero CAC score is associated with a 10-year cardiac mortality rate that approaches zero in the absence of other high-risk features.[7] Critically, a zero CAC score does not mean zero cardiovascular risk — it means no detectable calcified plaque at this point in time. Lp(a)-driven disease, very early atherosclerosis, and non-calcified (soft) plaque are not detected by CAC scoring.
CAC 1–99
Mild to moderate plaque burden. Risk is elevated above the zero-CAC population. A score in this range typically supports statin therapy consideration in patients who were previously in a treatment gray zone, and intensification of lifestyle modification.
CAC 100–299
Moderate plaque burden. Substantially elevated cardiovascular risk. At this level, statin therapy is generally indicated according to current ACC/AHA guidelines. Further risk stratification with CCTA may be appropriate in selected patients.
CAC ≥ 300
High plaque burden. Associated with a 10-year MACE rate approaching 20% in MESA data. Statin therapy and comprehensive cardiovascular risk reduction are strongly indicated. This score level should also prompt evaluation for other cardiovascular risk factors and consideration of cardiology referral.
Percentile Interpretation
Absolute CAC score is supplemented by age/sex/ethnicity-specific percentile ranking using MESA reference data. A CAC score of 75 at age 45 represents a substantially higher percentile rank — and higher cardiovascular risk — than the same score at age 70. Scores at or above the 75th percentile for age/sex/ethnicity are considered elevated in the 2018 ACC/AHA framework regardless of absolute score.
Who Should Consider CAC Scoring?
Strong Indications
Intermediate-risk adults (10-year ASCVD risk 7.5–20%): These patients are precisely the population the CAC score is designed to serve. When standard risk equations place a patient in a treatment gray zone, CAC provides definitive anatomic information about whether subclinical atherosclerosis is present — resolving the clinical uncertainty with direct evidence.
Patients reluctant to initiate statin therapy: A CAC score of zero provides legitimate, evidence-based reassurance that supports a shared decision to defer pharmacologic therapy and pursue lifestyle optimization — while committing to reassessment in 3–5 years.
Patients with risk factors incompletely captured by standard equations: Family history of premature cardiovascular disease, elevated Lp(a), chronic inflammatory conditions (psoriasis, rheumatoid arthritis, HIV).
Patients with competing risk conditions: Chronic kidney disease, diabetes — populations in whom standard risk equations may underestimate vascular disease burden.
Potentially Beneficial
Lower-risk adults (10-year ASCVD risk 5–7.5%) with risk-enhancing factors: The 2019 ACC/AHA primary prevention guidelines identify CAC as "reasonable" in lower-risk patients with features suggesting elevated risk not captured by standard equations.
Patients with apparent low risk but strong family history: When a parent had a premature MI and the patient's own risk score appears low, CAC provides objective anatomic context.
Not Routinely Indicated
High-risk adults already on maximal medical therapy: CAC does not change management in patients where statin therapy is already clearly indicated and optimized. It will not add value for a patient with established CAD, prior MI, or 10-year risk > 20%.
Symptomatic patients with chest pain or anginal equivalents: These patients need diagnostic cardiac evaluation (exercise stress testing, CCTA, or coronary angiography), not screening.
Very young adults (< 40) without specific risk-enhancing factors: Atherosclerotic calcification is rarely detectable before middle age; a CAC of zero in a 35-year-old provides limited reassurance.
CAC Scoring vs. CT Coronary Angiography (CCTA)
CAC scoring detects calcified plaque only. It is a screening test — low-dose, fast, inexpensive (approximately $100 at many centers), and highly validated for risk prediction. It cannot visualize non-calcified (soft) plaque, assess luminal stenosis, or characterize plaque morphology.
CCTA provides 3D anatomic imaging of the coronary arteries, visualizing both calcified and non-calcified plaque, luminal diameter, stenosis severity, and — with advanced post-processing tools (CLEERLY, HeartFlow) — plaque vulnerability markers and functional significance of stenosis. CCTA is superior to CAC scoring for anatomic characterization, intermediate stenosis evaluation, and plaque vulnerability assessment. It requires intravenous contrast and involves a higher radiation dose, though modern CT platforms have substantially reduced radiation exposure.
In the AnalogPM evaluation framework: CAC scoring is included in the Pipeline tier as a primary prevention screening tool for appropriate candidates. CCTA is included in the Nazaré tier for patients seeking the most comprehensive coronary anatomic evaluation available outside of invasive angiography. The SCOT-HEART and PROMISE trials have demonstrated that CCTA provides superior anatomic characterization compared to functional stress testing and leads to more targeted preventive therapy in intermediate-risk patients.[8]
Strengths and Limitations
Strengths
- —Validated predictive accuracy: strongest imaging-based risk predictor in primary prevention, with outcome data from tens of thousands of patients
- —Guideline-endorsed: formally incorporated into 2018 ACC/AHA cholesterol and 2019 ACC/AHA primary prevention guidelines
- —The power of a zero score: no other widely available test provides the same level of near-term cardiovascular risk reassurance
- —Low cost: approximately $75–$205 at most imaging centers; no contrast required
- —Motivational: communication of CAC scores improves adherence to lifestyle modification and medication[9]
Limitations
- —Detects only calcified plaque: non-calcified "soft" plaque is not visualized; a zero score does not exclude soft plaque
- —Radiation exposure: approximately 1–3 mSv; a consideration in very young patients and those with anticipated repeat scanning
- —Cannot assess stenosis severity: tells you how much calcium is present, not whether any plaque is obstructing blood flow
- —Static snapshot: plaque can progress; repeat scanning at 3–5 year intervals is appropriate in some patients
- —Does not replace comprehensive risk factor assessment: must be interpreted alongside clinical history, biomarkers, and genomic data
Cost and Accessibility
CAC scoring is widely available at most major radiology and cardiology imaging centers. At self-pay rates, CAC scoring typically costs $75–$205 (CPT 75571). Insurance coverage varies; many payers cover CAC scoring for intermediate-risk patients with formal indications, but out-of-pocket pricing makes it accessible even without coverage. The examination is completed in under 15 minutes with immediate results. Effective radiation dose ranges from approximately 1–3 mSv on modern scanners — comparable to the natural background radiation exposure over 3–12 months of daily life.
Conclusion
Coronary artery calcium scoring is the most validated imaging-based tool available for cardiovascular risk stratification in primary prevention. Its strengths — particularly the extraordinary predictive power of a zero score and its ability to resolve clinical uncertainty in intermediate-risk patients — are supported by the largest prospective cardiovascular imaging datasets in medicine. Its limitations, including inability to detect non-calcified plaque and absence of stenosis assessment, are real and should be clearly communicated.
“When incorporated into a comprehensive cardiometabolic evaluation that includes advanced biomarkers, genomic risk, and physician-led synthesis, CAC scoring transforms cardiovascular risk assessment from probability estimation to anatomic reality.”
References
- 1.Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008;117(22):2938–2948.
- 2.Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15(4):827–832.
- 3.Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358(13):1336–1345.
- 4.Budoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary calcification. J Am Coll Cardiol. 2007;49(18):1860–1870.
- 5.Polonsky TS, McClelland RL, Jorgensen NW, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA. 2010;303(16):1610–1616.
- 6.Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285–e350.
- 7.Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease. Circulation. 2016;133(9):849–858.
- 8.Newby DE, Adamson PD, Berry C, et al. Coronary CT angiography and 5-year risk of myocardial infarction (SCOT-HEART). N Engl J Med. 2018;379(10):924–933.
- 9.Kalia NK, Miller LG, Nasir K, et al. Visualizing coronary calcium is associated with improvements in adherence to statin therapy. Atherosclerosis. 2006;185(2):394–399.
- 10.Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. J Am Coll Cardiol. 2019;74(10):e177–e232.
Dr. RP, MD is dual board-certified in Emergency Medicine and Critical Care Medicine and is the founder of Analog Precision Medicine, a precision medicine practice in Southern California. This article is for educational purposes only and does not constitute medical advice or establish a physician-patient relationship.
← Back to Blog